Replies to post #167617 on Biotech Values

[oc631]

One possible explanation is they didn't have much if any data of the combo on HIV patients

It's possible but I would expect more from ABBV. The cynical theory is they got cold feet testing GT1A cirrhotic patients alone in a separate trial.